OIM
TVRD

Oder Investment Management’s Tvardi Therapeutics TVRD Stock Holding History

Oder Investment Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-8
Closed -$5K – 513
2020
Q4 		$5K Buy
+8
New +$4.19K ﹤0.01% 433

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Oder Investment Management's TVRD Position: Q1 2021 in Review

Oder Investment Management sold out of Tvardi Therapeutics (TVRD) in Q1 2021, closing a stake of 8 shares — an estimated $5K sold.

Oder Investment Management first reported a position in TVRD in Q4 2020 and held it in 1 quarter. The position peaked at $5K in Q4 2020. 167 funds tracked by Wall St. Rank hold TVRD as of Q1 2021.

  • Oder Investment Management reported no remaining Tvardi Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Oder Investment Management sold 8 Tvardi Therapeutics shares in Q1 2021, an estimated $5K.
  • Oder Investment Management first reported a position in Tvardi Therapeutics in Q4 2020 and held it in 1 quarter.
  • Oder Investment Management's Tvardi Therapeutics position peaked at $5K in Q4 2020.
  • 167 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2021.

Based on Oder Investment Management's 13F filing for Q1 2021, filed 10 May 2021.